Hepatitis c schistosomiasis
Subject has adequate understanding of the procedures of the study and agrees to abide strictly thereby.
Subject is able to communicate well with the investigator, is available to attend all study visits. Subject will remain within Europe excluding Corsica during the study period and is reachable by mobile telephone from week 3 to week 12 of the study period. Subject agrees to refrain from blood donation throughout the study period.
For female subjects: subject agrees to use adequate contraception and not to breastfeed for the duration of study. Subject has signed informed consent. Exclusion Criteria: 1.
Any history, or evidence at screening, of clinically significant symptoms, physical signs or abnormal laboratory values suggestive of systemic conditions, such as cardiovascular, pulmonary, hepatitis c schistosomiasis, hepatic, neurological, dermatological, endocrine, malignant, haematological, infectious, immune-deficient, psychiatric and other disorders, which could compromise the health of the volunteer during the study or interfere with the interpretation of the study results.
These include, but are not limited to, any of the following: - body weight The chronic use of any drug known to interact with praziquantel, or artesunate or lumefantrine metabolism e.
For female subjects: positive urine pregnancy test at screening. Any history of schistosomiasis or treatment for schistosomiasis. Positive serology for schistosomiasis or elevated serum or urine circulating anodic antigen or positive Schistosoma serology at baseline.
Known hypersensitivity to or contra-indications including co-medication for use of praziquantel or, hepatitis c schistosomiasis or lumefantrine. Being an employee or student of the department of parasitology or infectious diseases of the Leiden University Medical Center.